WO2013151314A1 - Composition comprenant de la vimentine pour inhiber la perte des cheveux ou favoriser la pousse des cheveux - Google Patents

Composition comprenant de la vimentine pour inhiber la perte des cheveux ou favoriser la pousse des cheveux Download PDF

Info

Publication number
WO2013151314A1
WO2013151314A1 PCT/KR2013/002743 KR2013002743W WO2013151314A1 WO 2013151314 A1 WO2013151314 A1 WO 2013151314A1 KR 2013002743 W KR2013002743 W KR 2013002743W WO 2013151314 A1 WO2013151314 A1 WO 2013151314A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
protein
mentin
composition
nucleic acid
Prior art date
Application number
PCT/KR2013/002743
Other languages
English (en)
Korean (ko)
Inventor
정지형
장양수
장홍선
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120112421A external-priority patent/KR20130112674A/ko
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Publication of WO2013151314A1 publication Critical patent/WO2013151314A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to a composition for inhibiting hair loss or promoting hair growth comprising bimentin.
  • Human hair is primarily responsible for the protective function to protect the scalp from external stimuli such as ultraviolet rays and aesthetic functions to express the external image of the individual.
  • external stimuli such as ultraviolet rays and aesthetic functions to express the external image of the individual.
  • hair loss is frequently caused by natural factors such as environmental pollution, strong ultraviolet rays, and physiological factors such as stress and hormonal imbalance. Therefore, the need for materials for the prevention and treatment thereof is urgently needed.
  • Hair follicles the physiological organs in the body that make up the hair, form the hair during the postnatal development, the anagen phase in which the hair grows actively, the catagen phase in which the hair degenerates, and the hair fall out.
  • the hair cycle is divided into a telogen phase, an exogen phase in which hair loss is maintained, and is involved in hair growth, maintenance, and dropout.
  • the activity of the hair follicles is caused by dermal papilla cells, in particular the proliferation and differentiation of the dermal papilla cells is primarily involved in the progress of the hair growth cycle and hair formation (Botchkarev VA, Kishimoto J, Molecular control of epithelial-mesenchymal interactions).
  • the prolonged growth phase by inhibiting the proliferation of the dermal papilla cells or the inhibition of cell death and the shortening of the degenerative stage, resting period, and alopecia will be improved and treated. It is feed.
  • cell division and migration near the nipple are closely related to the growth of the hair. During the growth phase, new hair is generated from the nipple, which is activated by various cytokines and hormones, resulting in cell migration to the nipple.
  • growth factors such as vertican, IGF-1, and VEGF are most strongly expressed in the growth phase and decreased in the degenerative and resting phases to induce the growth of dermal papilla cells and to maintain the hair growth phase.
  • Vertican a versatile extracellular matrix proteoglycan in cell biology.Current Opinion Cell Biol 14, 617-623, 2002, Kulessa H, Turk G, Inhibition of Bmp signaling affects growth and differentiation in the anagen hair follicle, EMBO J 19, 6664-6674, 2000).
  • minoxidil and finasteride which are currently approved by the FDA, have side effects such as systemic hair growth and decreased sexual function, and the specific mechanism of action of minoxidil is not clear. Therefore, it is necessary to develop a biological material that promotes proliferation of dermal papilla cells in hair follicles and increases expression of growth factors while having less concern about side effects.
  • the present inventors have completed the present invention by experimentally confirming that the non-mentin protein promotes the growth and migration of dermal papilla cells and increases the expression of growth factors such as IGF-1.
  • an object of the present invention is to provide a new use of non-mentin to promote the growth and migration of dermal papilla cells and to increase the expression of growth factors such as IGF-1.
  • the present invention provides a composition for preventing hair loss or promoting hair growth comprising a non-mentin protein as an active ingredient.
  • the present invention provides a composition for preventing hair loss or promoting hair growth comprising a fusion protein combined with a non-mentin protein and a protein delivery domain as an active ingredient.
  • the present invention provides a composition for preventing hair loss or promoting hair growth comprising a nucleic acid encoding a non-mentin protein as an active ingredient.
  • the present invention provides a composition for preventing hair loss or promoting hair growth comprising a nucleic acid encoding a fusion protein combined with a non-mentin protein and a protein delivery domain as an active ingredient.
  • the present invention is a hair loss prevention or hair growth comprising at least one selected from the group consisting of non-mentin protein, protein delivery domain-non-mentin fusion protein and a nucleic acid encoding the protein as an active ingredient Provide accelerators.
  • the present invention is a hair loss prevention or hair growth comprising at least one selected from the group consisting of non-mentin protein, protein delivery domain-non-mentin fusion protein and the nucleic acid encoding the protein as an active ingredient Providing promotion cosmetics.
  • non-mentin promotes the growth and migration of dermal papilla cells and expression of growth factors, and can be usefully used as a drug or cosmetic material for the purpose of inhibiting hair loss and treating hair growth with this effect.
  • Figure 1 shows a cleavage map of the pHis / TAT- non-mentin expression vector.
  • Figure 2 is transformed in Escherichia coli by introducing a non-mentin gene of human in a pHis / TAT expression vector and stained with Coomassie brilliant blue of the protein delivery domain-non-mentin recombinant protein obtained through protein expression and purification One result is shown.
  • 3 is a cell proliferation ELISA analysis using BrdU (5-bromo-2'-deoxyuridine) for the degree of cell proliferation when the protein delivery domain-non-mentin fusion protein is treated by concentration in the dermal papilla cells isolated from the rats. It is a graph obtained through [1, control; 2, non-mentin 10 nM treatment; 3, non-mentin 100 nM treatment; 4, non-mentin 1 uM treatment; 5, non-mentin 10 uM treatment; 6, GFP 1 uM treatment].
  • Figure 4 shows the result of measuring the degree of cell migration when treated with protein delivery domain-non-mentin fusion protein concentration to the dermal papilla cells [wound healing assay] [1, immediately after wound healing; 2, non-mentin 10 nM treatment; 3, non-mentin 100 nM treatment; 4, non-mentin 1 uM treatment; 5, non-mentin 10 uM treatment; 6, GFP 1 uM treatment].
  • Figure 5 shows the results of the reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the expression levels of growth factors IGF-1 and VEGF by treating the protein delivery domain-non-mentin fusion protein to the dermal papilla cells [lane 1 , Control; Lane 2, non-mentin 10 nM treatment; Lane 3, non-mentin 100 nM treatment; Lane 4, non-mentin 1 uM treatment].
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • Figure 6 is a photograph confirming the hair growth effect by applying the TAT- non-mentin fusion protein to the rat hair root removed.
  • FIG. 7 is a photograph showing the hair growth effect after saline, TAT-GFP, minoxidil, TAT- non-mentin fusion protein of Example 1 were respectively treated in a mouse model from which hair root was removed.
  • Figure 8 was treated with saline, TAT-GFP, minoxidil, TAT- non-mentin fusion protein of Example 1 in the mouse model from which the hair root was removed, and after 23 days, the mouse head, torso, tail, etc. It is the photograph which photographed the thickness of the hair of the site (up) and the graph which shows the thickness of the hair of the torso (bottom).
  • the present invention is characterized by the fact that non-mentin can promote the proliferation of papillary cells and increase the expression of growth factors, thereby affecting the hair cycle and preventing and treating hair loss diseases.
  • non-mentin shows the effect of promoting the growth of dermal papilla cells.
  • non-mentin significantly increases dermal papilla cell proliferation.
  • the papilla cells experimental group treated with the protein delivery domain-non-mentin fusion protein showed a significant effect on the dermal papilla cell proliferation compared to their control group, and showed an increase in cell proliferation efficiency up to 300% or more compared to the control group (see FIG. 2).
  • When measuring the papillary cell proliferation effect of each non-mentin protein concentration showed the greatest effect at 1 uM concentration (see Figure 2).
  • the present invention shows the cell migration activation effect of non-mentin dermal papilla cells.
  • non-mentin significantly increases cell migration of dermal papilla cells.
  • the dermal papilla cells treated with the protein transfer domain-non-mentin fusion protein showed a significant effect on the dermal papilla cell migration compared to their control group (see FIG. 3).
  • the present invention shows the effect of promoting the expression of growth factor IGF-1 in non-mentin dermal papilla cells.
  • non-mentin increases the expression of growth factor IGF-1 in dermal papilla cells.
  • the dermal papilla cells treated with the protein transfer domain-non-mentin fusion protein showed an increase in IGF-1 expression compared to their controls (see FIG. 4).
  • the present invention provides a composition for preventing hair loss or promoting hair growth comprising non-mentin protein as an active ingredient.
  • the non-mentin protein included in the pharmaceutical composition of the present invention may be derived from a mammal including a human, and according to the individual to be treated, the origin of the non-mentin may be appropriately selected.
  • the non-mentin of the present invention may be derived from a human, and the amino acid sequence of the non-mentin derived from humans is known (SEQ ID NO: 1: GenBank acession no. NP — 003371.2).
  • non-mentin protein included in the pharmaceutical composition of the present invention may include both natural or recombinant non-mentin proteins or proteins having physiological activities substantially equivalent thereto. Proteins having substantially equivalent physiological activity include functional equivalents and / or functional derivatives of naturally occurring proteins or recombinant non-mentin proteins.
  • the “functional equivalent” is an amino acid sequence variant in which some or all of the naturally occurring protein amino acids are substituted, or a part of the amino acids are deleted or added, and at least 70%, preferably 80% or more, more preferably, with the non-mentin protein.
  • it refers to a protein having a sequence homology of 90% or more and exhibiting substantially homogeneous physiological activity with non-mentin protein.
  • the “functional derivative” refers to a protein in which some chemical structures have been modified to increase or decrease physicochemical properties while maintaining the basic skeleton and physiological activity of the non-mentin protein.
  • functional derivatives include proteins whose structure has been altered to alter the stability, shelf life, volatility or solubility of the non-mentin protein.
  • non-mentin protein represented by SEQ ID NO: 1.
  • the present invention provides a composition for preventing hair loss or promoting hair growth comprising a fusion protein combined with a non-mentin protein and a protein delivery domain as an active ingredient.
  • the protein delivery domain may include a trans-activating transcriptional activator (TAT) derived from human immunodeficiency virus type I (HIV-1); Antp (Antennapedia or penetratin) peptide, which is an antennapedia Homeodomain of Drosophila; Mutant phenotype protein 1 (Mph-1) of the mouse transcription factor, VP22 (viral protein 22) of Herpes simplex virus (HSV-1); Human protamine P4 (HP4) from herring protamine; Transportan, MAP (Model amphipathic peptide), TP10 (Transportan-10), CTP (Cardiac targeting peptide), K5-FGF (K5-fibroblast growth factor, AAVALLPAVLLALLP [SEQ ID NO: 11]), HAP-1 (Huntingtin) associated protein 1, SFHQFARATLAS [SEQ ID NO: 12]), 293P-1 (SNNNVRPIHIWP [SEQ ID NO: 13]), CADY (cystea a
  • TAT- non-mentin fusion protein SEQ ID NO: 2 was used.
  • the PTD-non-mentin fusion protein of the present invention obtains DNA fragments from non-mentin genes by PCR and then introduces them into plasmid vectors (such as prokaryotic expression vector pET or eukaryotic expression vector pcDNA) containing PTD. After transforming the cells to express the protein, it can be prepared through an appropriate protein purification process.
  • plasmid vectors such as prokaryotic expression vector pET or eukaryotic expression vector pcDNA
  • the present invention also includes a composition for preventing hair loss or promoting hair growth comprising a nucleic acid encoding a non-mentin protein or a nucleic acid encoding a fusion protein in which a non-mentin protein and a protein delivery domain are bound.
  • Nucleic acids encoding the non-mentin protein or PTD-non-mentin fusion protein include DNA or RNA.
  • the nucleic acid encoding the non-mentin protein may be derived from a mammal, more preferably a human.
  • the human nonmentin gene is known (SEQ ID NO: 3, GenBank accession no. BC000163).
  • the nucleic acid encoding the PTD-non-mentin fusion protein includes a gene represented by SEQ ID NO: 4.
  • the nucleic acid is introduced into an expression vector, such as a plasmid or viral vector, by known methods and then the expression vector is expressed phenotypicly by infection or transduction by various methods known in the art. Can be introduced.
  • an expression vector such as a plasmid or viral vector
  • the plasmid expression vector is a method of delivering plasmid DNA directly to human cells by FDA's approved gene transfer method for human use (Nabel, E. G., et al., Science, 249: 1285-1288, 1990). Plasmid DNA has the advantage that it can be homogeneously purified unlike viral vectors.
  • mammalian expression plasmids known in the art can be used as the plasmid expression vector that can be used in the present invention.
  • mammalian expression plasmids known in the art can be used.
  • pET, pcDNA, pRK5 European Patent No. 307,247)
  • pSV16B International Patent Publication No. 91/08291
  • pVL1392 PharMingen
  • the pHis / TAT plasmid prepared by the present team was used.
  • Plasmid expression vectors comprising the nucleic acid are methods known in the art, such as, but not limited to, transient transfection, microinjection, transduction, cell fusion, Calcium phosphate precipitation, liposome-mediated transfection, DEAE Dextran-mediated transfection, polybrene-mediated transfection, electroinvasion It can be introduced into tumor cells by electroporation, gene guns and other known methods for introducing DNA into cells (Wu et al., J. Bio. Chem., 267: 963-). 967, 1992; Wu and Wu, J. Bio. Chem., 263: 14621-14624, 1988). Preferably, transient transfection methods can be used.
  • viral expression vectors including the nucleic acid include, but are not limited to, retroviruses, adenoviruses, adenoviruses, herpes viruses, avidoxviruses, and the like.
  • the retroviral vector is constructed such that all of the viral genes have been removed or altered so that non-viral proteins are made in the cells infected by the viral vector.
  • the main advantages of retroviral vectors for gene therapy are to deliver large quantities of genes in cloned cells, to correctly integrate genes transferred into cellular DNA, and to not cause subsequent infections after gene transfection (Miller, AD, Nature). , 1992, 357: 455-460).
  • FDA-certified retroviral vectors were prepared using PA317 amphoteric retrovirus package cells (Miller, A.D. and Buttimore, C., Molec. Cell Biol., 6: 2895-2902, 1986).
  • Non-retroviral vectors include adenoviruses as mentioned above (Rosenfeld, MA, et al., Cell, 68: 143-155, 1992; Jaffe, HA et al., Nature Genetics, 1: 372- 378, 1992; Lemarchand, P. et al., Proc. Natl. Acad. Sci. USA, 89: 6482-6486, 1992).
  • the main advantage of adenoviruses is that they carry large amounts of DNA fragments (36 kb genomes) and have the ability to infect non-replicating cells with very high titers.
  • Herpes viruses can also be usefully used for human gene therapy (Wolfe, J.H., et al., Nature Genetics, 1: 379-384, 1992).
  • suitable known viral vectors can be used in the compositions of the present invention.
  • composition for inhibiting hair loss and promoting hair growth may be prepared as a pharmaceutical composition or a cosmetic composition, and may be prepared as a medicine or cosmetics, and when prepared as a medicine, orally or intravenously, subcutaneously, intranasally or intraperitoneally. It is administered quadrature. Oral administration also includes sublingual application. Parenteral administration includes injection and drip methods such as subcutaneous injection, intramuscular injection and intravenous injection.
  • composition comprising the non-mentin protein, PTD-non-mentin fusion protein or nucleic acid encoding the protein as an active ingredient according to the present invention may be prepared and administered in the form of various formulations by further including a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier may be prepared and administered in the form of various formulations by further including a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable refers to a composition which is physiologically acceptable and does not cause an allergic reaction or similar reaction, such as gastrointestinal disorders, dizziness or the like, when administered to a human.
  • Pharmaceutically acceptable carriers may include binders, suspending agents, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments and flavoring agents for oral administration, and in the case of injections, buffers, preservatives, analgesics Solubilizers, isotonic agents and stabilizers can be used in combination, and in the case of topical administration agents, bases, excipients, lubricants and preservatives can be used.
  • the formulation of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with the pharmaceutically acceptable carrier as described above.
  • oral administration in the case of oral administration, it may be prepared in the form of tablets, tpoky, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, may be prepared in unit dosage ampoules or in multiple dosage forms.
  • the pharmaceutical composition of the present invention can be prepared according to techniques commonly used in the form of various formulations.
  • Hair loss prevention or hair growth promoting composition according to the present invention can be administered in a pharmaceutically effective amount.
  • the 'pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment. Effective dose levels are well known in factors such as disease type, severity, age, sex, drug activity, drug sensitivity, time of administration, route of administration and rate of release, duration of treatment, drugs used concurrently, and other medical fields in a patient. It can be determined according to the factor.
  • the composition of the present invention may be administered alone or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents.
  • the active ingredient preferably comprises 0.01 to 30 parts by weight, more preferably 0.1 to 20 parts by weight based on 100 parts by weight of the total hair loss prevention or hair growth promoting composition.
  • the present invention may include a hair loss prevention or hair growth promoting agent comprising at least one selected from the group consisting of a non-mentin protein, a protein delivery domain-non-mentin fusion protein, and a nucleic acid encoding the protein.
  • the present invention may include a cosmetic for preventing hair loss or promoting hair growth comprising at least one selected from the group consisting of a non-mentin protein, a protein delivery domain-non-mentin fusion protein, and a nucleic acid encoding the protein.
  • the cosmetics of the present invention further contain a cosmetically acceptable carrier to be prepared in conventional formulations such as creams, lotions, tonics, sprays, aerosols, oils, solutions, suspensions, gels, ointments, emulsions, waxes, pastes and the like.
  • a cosmetically acceptable carrier to be prepared in conventional formulations such as creams, lotions, tonics, sprays, aerosols, oils, solutions, suspensions, gels, ointments, emulsions, waxes, pastes and the like.
  • Cosmetically acceptable carrier to be prepared in conventional formulations such as creams, lotions, tonics, sprays, aerosols, oils, solutions, suspensions, gels, ointments, emulsions, waxes, pastes and the like.
  • the composition of the present invention usually contains a base, and other components generally used as cosmetic raw materials may be appropriately blended as necessary.
  • the base of the composition of the present invention may be used as long as
  • composition of the present invention examples include, but are not limited to, surfactants, emulsifiers, thickeners, preservatives (eg, methyl paraoxybenzoate), antioxidants, fragrances, and the like.
  • the cosmetics of the present invention may include components that may serve to supply nutrients to hair follicles or hair growth promoting auxiliary components that are commonly used.
  • vitamins, amino acids, animal and vegetable oils, sodium chloride And the like but are not limited to these. Their amount is preferably 0.0001 to 10% by weight, in particular 0.01 to 1% by weight of the total composition.
  • the vitamins include, but are not limited to, vitamin A, vitamin B1, vitamin B2, niacin (nicotinic acid), vitamin C, vitamin E, sodium pantothenate, potassium pantothenate, biotin H (vitamin H), and the like.
  • Amino acids include, but are not limited to, waveguides.
  • Animal and vegetable oils include, but are not limited to, horse oil, egg oil, olive oil, camellia oil, rapeseed oil, sesame oil, germ oil, and the like.
  • the cosmetic of the present invention can be used by a method such as applying or spreading directly on the hair or the scalp.
  • Hair to which the composition of the present invention is applied includes hair follicles and hair follicles of the head, hair and eyelashes, and eyelashes, beards, armpits, pubic hair, and all parts of the hair root and hair follicles throughout the body. Therefore, the present invention hair tonic, hair lotion, hair cream, hair spray, hair mousse, hair gel, hair conditioner, hair shampoo, hair rinse, hair pack, hair treatment, eyebrow hair regrowth agent, eyelash regrowth agent, eyelash nutrient, pet shampoo , Pet rinse, and the like.
  • the protein delivery domain-non-mentin protein used in the present invention was prepared by recombinant protein expression and purification using a pHis / TAT expression vector (Kwon JH et al., 2007, Biochem Biophys Res Commun., 363, 399-404). Was done.
  • PCR fragments were obtained by DNA fragments (SEQ ID NO: 3), cut into respective restriction enzymes (BamHI / SalI), and put into a pHis / TAT expression vector to prepare a recombinant expression vector pHis / TAT-Vimentin [FIG. ) Was transduced.
  • IPTG isopropyl- ⁇ -D-thio-galactoside
  • SEQ ID NO: 2 protein-transfer domain-nonmentin fusion protein
  • Example 2 Proliferation effect of dermal papilla cells by non-mentin
  • the dermal papilla cells obtained from the back skin of SD-rat were identified morphologically, and were identified as the dermal papilla cells by measuring ALP activity (alkaline phosphatase activity), vertican and nexin expression as biological markers.
  • the cells were cultured in DMEM medium containing 10% FBS and antibiotics (penicillin streptomycin). On day 3 of culture, the cells were transferred to 96-well plates in a culture dish. After attaching the cells, the protein delivery domain-non-mentin protein was added to the medium by concentration, and then cultured for 2 hours, and then changed to a new medium, and further cultured for 72 hours under conditions of 5% CO 2 and 37 °C.
  • each papillary cell group treated with non-mentin protein concentration was cultured for 24 hours, and cell proliferation was performed using BrdU enzyme immunoassay kit (Millipore). After completion of the reaction, it was confirmed that the amount of dermal papilla cells increased significantly with concentration compared to the control group by reading with a 450 nm absorbance meter [FIG. 3].
  • the TAT-GFP protein treatment prepared in the same manner as the TAT-non-mentin protein preparation is a control to show that the hair growth effect is due to the entering non-mentin, not the effect of TAT.
  • Example 3 migration effect of dermal papilla cells by non-mentin
  • a wound healing assay was performed to observe the effect on the movement of dermal papilla cells.
  • the dermal papilla cells were incubated in 6-well plates with DMEM medium containing 10% FBS, treated with non-mentin for 2 hours in DMEM medium containing 5% FBS, and wound with a pipette tip. The cells were further incubated for 24 hours under conditions of 5% CO2 and 37 ° C in DMEM medium and observed under a microscope. As a result, it was confirmed that as the concentration of the TAT- non-mentin fusion protein increases, the flow of all the flow cells increases [FIG. 4].
  • mRNA was extracted using the mRNA extraction kit (Geneol). CDNA was synthesized using reverse transcriptase (Gendepot, M-MLV) and PCR was performed using Taq polymerase.
  • Primers used for PCR to confirm the expression of IGF-1 were 5-TCAACAAGCCCACAGCAACAGGGTAT-3 (SEQ ID NO: 7), 5-ACTCGTGCAGAGCAAAGGAT-3 (SEQ ID NO: 8).
  • Primers used for PCR to confirm the expression of VEGF were 5 '-GACCCTGGTGGACATCTTCCAGGA-3' (SEQ ID NO: 9), 5'-GGTGAGAGGTCTAGTTCCCGA-3 '(SEQ ID NO: 10).
  • the result of the PCR reaction was confirmed by electrophoresis on 1.3% agarose gel, through which the expression levels of growth factors IGF-1 and VEGF were confirmed. As a result, it was confirmed that the expression of IGF-1 and VEGF is promoted as the concentration of the TAT- non-mentin fusion protein is higher [Fig. 5].
  • the skin of the mouse (C57BL / 6 mouse) was applied with a depilatory cream (Veet, Oxy Rekitbenzer, Korea) and after 3 minutes, the spatula was scraped off to remove hair and hair roots, and then wiped with buffer PBS.
  • the surface of the epidermis of the rat was pushed to remove dead skin cells, and then further dead skin cells were removed using a transparent tape.
  • 20 ⁇ g of the TAT-non-mentin fusion protein of Example 1 was applied thereto, and then beated for 30 seconds to be absorbed.
  • the saline (saline) treatment group, TAT-GFP treatment group, minoxidil (Minoxidil) 1% 50 ⁇ treatment group was also tested at the same time.
  • FIG. 7 shows photographs of the results after 23 days of treatment.
  • the TAT-non-mentin fusion protein treatment group of Example 1 had the best hair growth effect.
  • Figure 8 is a photograph taken by taking the thickness of the hair in the middle of each group of mice, the thickness of the TAT- non-mentin fusion protein treatment group of Example 1 was the thickest, hair follicles through H & E staining after sacrifice As a result of confirming the hair follicle, it was confirmed that the number of activated round follicles of round shape was increased in the TAT-non-mentin fusion protein treatment group of Example 1 [FIG.

Abstract

La présente invention concerne les utilisations de la vimentine, qui présente les fonctions de favoriser la prolifération des cellules de papille dermique et d'augmenter la migration cellulaire et l'expression du facteur de croissance. Plus particulièrement, la présente invention se rapporte à de nouvelles utilisations de la vimentine pour favoriser la prolifération des cellules de papille dermique qui sont différenciées en kératinocytes, en mélanocytes et similaires à partir de follicules pileux de manière à faire pousser les cheveux et à maintenir les follicules pileux, ce qui permet d'empêcher la chute des cheveux. Selon la présente invention, la composition de la présente invention peut être utilisée efficacement dans l'inhibition de la perte des cheveux et pour favoriser la croissance des cheveux à travers la prolifération de la vimentine.
PCT/KR2013/002743 2012-04-03 2013-04-03 Composition comprenant de la vimentine pour inhiber la perte des cheveux ou favoriser la pousse des cheveux WO2013151314A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20120034521 2012-04-03
KR10-2012-0034521 2012-04-03
KR10-2012-0112421 2012-10-10
KR1020120112421A KR20130112674A (ko) 2012-04-03 2012-10-10 비멘틴을 포함하는 탈모 억제 또는 발모 촉진용 조성물
KR10-2013-0035733 2013-04-02
KR1020130035733A KR101349300B1 (ko) 2012-04-03 2013-04-02 비멘틴을 포함하는 탈모 억제 또는 발모 촉진용 조성물

Publications (1)

Publication Number Publication Date
WO2013151314A1 true WO2013151314A1 (fr) 2013-10-10

Family

ID=49300744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/002743 WO2013151314A1 (fr) 2012-04-03 2013-04-03 Composition comprenant de la vimentine pour inhiber la perte des cheveux ou favoriser la pousse des cheveux

Country Status (1)

Country Link
WO (1) WO2013151314A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034281A1 (fr) * 2000-10-20 2002-05-02 North Shore-Long Island Jewish Research Institute Procede favorisant la croissance des cheveux
US20070265185A1 (en) * 2004-09-17 2007-11-15 Genome Express Sa Phosphorylated Vimentin Serving as a Marker of the Aggressiveness and/or Invasiveness of Tumors
US20090155822A1 (en) * 2005-06-27 2009-06-18 Holger Bang Process for diagnosing rheumatic diseases
US7670604B2 (en) * 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US20120021974A1 (en) * 2007-07-13 2012-01-26 Ibcc Holding As Novel inhibitor of angiogenesis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034281A1 (fr) * 2000-10-20 2002-05-02 North Shore-Long Island Jewish Research Institute Procede favorisant la croissance des cheveux
US7670604B2 (en) * 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US20070265185A1 (en) * 2004-09-17 2007-11-15 Genome Express Sa Phosphorylated Vimentin Serving as a Marker of the Aggressiveness and/or Invasiveness of Tumors
US20090155822A1 (en) * 2005-06-27 2009-06-18 Holger Bang Process for diagnosing rheumatic diseases
US20120021974A1 (en) * 2007-07-13 2012-01-26 Ibcc Holding As Novel inhibitor of angiogenesis

Similar Documents

Publication Publication Date Title
US6639051B2 (en) Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
Franceschi et al. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7
Suzuki et al. Mesoderm induction by BMP-4 and-7 heterodimers
Peters et al. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist
US20060270621A1 (en) Inhibition of hair growth with RNAi targeting desmoglein 4 and nude mRNAs
US20080020993A1 (en) Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules
KR20040021598A (ko) Ｕｖｂ-유발 피부손상 방지 방법
WO2016163806A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux
US20120165270A1 (en) Inhibition of hair follicle growth by the wnt inhibitor dkk1
JP2005519591A (ja) 毛包成長
KR101349300B1 (ko) 비멘틴을 포함하는 탈모 억제 또는 발모 촉진용 조성물
JPH10279501A (ja) 育毛剤
JP6916318B2 (ja) 尿細胞からケラチノサイト幹細胞への直接逆分化方法および逆分化したケラチノサイト幹細胞を利用した皮膚再生促進用組成物の製造方法
WO2018034453A1 (fr) Conjugué de minoxidil et d'un peptide
WO2013151314A1 (fr) Composition comprenant de la vimentine pour inhiber la perte des cheveux ou favoriser la pousse des cheveux
EP2138158B1 (fr) Agent inhibiteur de croissance des poils
KR101721228B1 (ko) 지방유래 줄기세포의 배양액을 유효성분으로 포함하는 발모촉진용 조성물
AU760252B2 (en) Modulation of cell proliferation, methods and reagents
ES2213161T3 (es) Metodos para inducir el crecimiento del pelo y la coloracion.
WO2021182866A1 (fr) Composition pour traiter la chute des cheveux ou stimuler la pousse des cheveux comprenant un facteur de croissance
KR102187371B1 (ko) FoxQ1 유전자가 과발현된 지방유래 줄기세포 및 이의 용도
WO2010077093A9 (fr) Composition favorisant la croissance des cheveux ou empêchant la perte de cheveux comprenant de l'érythropoïétine
JP5582516B2 (ja) 繊維芽細胞増殖因子制御ペプチド
WO2014073919A1 (fr) Composition pour la prévention, le traitement ou la réduction de l'alopécie
WO2019103572A1 (fr) Composition comprenant un miarn pour la prévention de chute des cheveux ou la stimulation de repousse des cheveux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13771824

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13771824

Country of ref document: EP

Kind code of ref document: A1